-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143

Benzinga·05/07/2026 22:23:45
Listen to the news
Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $140 to $143.